Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001193125-25-180317
Filing Date
2025-08-14
Accepted
2025-08-14 06:40:39
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 13986
2 EX-99.1 ck0000000000-ex99_1.pdf EX-99.1 87443
  Complete submission text file 0001193125-25-180317.txt   136402
Mailing Address 444 WEST LAKE STREET 50TH FLOOR CHICAGO IL 60606
Business Address 444 WEST LAKE STREET 50TH FLOOR CHICAGO IL 60606 312.499.2999
BALYASNY ASSET MANAGEMENT L.P. (Filed by) CIK: 0001218710 (see all company filings)

EIN.: 364472709 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G

Mailing Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010 (212) 547-9879
Lexeo Therapeutics, Inc. (Subject) CIK: 0001907108 (see all company filings)

EIN.: 854012572 | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-94231 | Film No.: 251214173
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)